Adults 21 to 80, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Comparison of Body Fat Percentage Estimates to DXA References Classified by Body Mass IndexPrimary· within a single, 3-hour evaluation
Comparison of Body Fat Percentage estimates to DXA references classified by Body Mass Index
BMI < 25
Group
Value
95% CI
Smartphone Visual Body Composition (VBC)
2.50
± 1.8
FitBit Aria 2 (cBIA 1)
6.36
± 3.5
Tanita BF-684W (cBIA 2)
5.75
± 3.3
Renpho ES-24M-W/B (cBIA 3)
7.66
± 4.6
InBody S10 (pBIA1)
4.29
± 2.2
Quantum IV (pBIA 2)
4.41
± 2.8
BOD POD ADP
3.31
± 2.2
BMI 25-29.9
Group
Value
95% CI
Smartphone Visual Body Composition (VBC)
1.90
± 1.4
FitBit Aria 2 (cBIA 1)
3.02
± 2.3
Tanita BF-684W (cBIA 2)
5.04
± 14.3
Renpho ES-24M-W/B (cBIA 3)
6.00
± 4.9
InBody S10 (pBIA1)
2.49
± 1.4
Quantum IV (pBIA 2)
3.82
± 3.1
BOD POD ADP
2.30
± 1.9
BMI > 30
Group
Value
95% CI
Smartphone Visual Body Composition (VBC)
2.16
± 1.4
FitBit Aria 2 (cBIA 1)
4.44
± 1.8
Tanita BF-684W (cBIA 2)
4.31
± 3.6
Renpho ES-24M-W/B (cBIA 3)
4.60
± 4.6
InBody S10 (pBIA1)
2.63
± 2.0
Quantum IV (pBIA 2)
5.58
± 2.6
BOD POD ADP
3.67
± 2.3
Comparison of Body Fat Percentage Estimates to DXA References Classified by SexPrimary· within a single, 3-hour evaluation
Comparison of Body Fat Percentage estimates to DXA references classified by Sex
Male Participants
Group
Value
95% CI
Smartphone Visual Body Composition (VBC)
1.88
± 1.3
FitBit Aria 2 (cBIA 1)
4.53
± 5.0
Tanita BF-684W (cBIA 2)
6.23
± 13.4
Renpho ES-24M-W/B (cBIA 3)
4.11
± 3.3
InBody S10 (pBIA1)
3.37
± 2.4
Quantum IV (pBIA 2)
5.01
± 3.0
BOD POD ADP
3.50
± 2.4
Female Participants
Group
Value
95% CI
Smartphone Visual Body Composition (VBC)
2.34
± 1.6
FitBit Aria 2 (cBIA 1)
4.45
± 3.3
Tanita BF-684W (cBIA 2)
4.10
± 3.1
Renpho ES-24M-W/B (cBIA 3)
6.89
± 5.3
InBody S10 (pBIA1)
2.98
± 1.8
Quantum IV (pBIA 2)
4.54
± 2.9
BOD POD ADP
2.90
± 2.1
Sponsor's own description
This research study is designed to validate the precision and accuracy of body measurement and composition results from a novel 2D imaging device that operates through a smart-phone application. Measurement references will be obtained through dual energy x-ray absorptiometry, air displacement plethysmography, bioelectrical impedance analysis, manual anthropometry, and previously validated 3D optical scanners.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee
· Phase 3
· recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart
· Phase 3
· recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl
· Phase 1
· recruiting
Other Pennington Biomedical Research Center trials
Trials by the same sponsor.
NCT07530718 — Body Composition Outcomes in MS Patients
· not yet recruiting
NCT07095972 — Continuous Glucose Monitoring in Metabolic Surgery
· NA
· not yet recruiting
NCT07139821 — Dietary Iron Requirements
· recruiting
NCT07318064 — Ultra-processed Food Consumption and Health Pilot Study
· NA
· not yet recruiting
NCT07305753 — CanCan Body Composition Study
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pennington Biomedical Research Center
Last refreshed: 22 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04854421.